Human Beta-Defensin 1
Constitutively expressed antimicrobial peptide of the beta-defensin family, providing baseline mucosal and epithelial innate immunity.
Chemical Identity
| Property | Value |
|---|---|
| Gene | DEFB1 |
| Chromosome | 8p23.1 |
| Molecular Weight | ~3.9 kDa |
| Amino Acids | 36 (mature peptide) |
| Peptide Class | Beta-Defensin |
| Disulfide Bonds | 3 (Cys1-Cys5, Cys2-Cys4, Cys3-Cys6) |
Structure
Human beta-defensin 1 (hBD-1) is a 36-amino acid cationic peptide containing six cysteine residues that form three intramolecular disulfide bonds in a characteristic beta-defensin pattern (Cys1-Cys5, Cys2-Cys4, Cys3-Cys6). The peptide adopts a compact beta-sheet structure stabilized by the disulfide network. hBD-1 is produced as a 68-amino acid precursor that is processed to the mature form.
Mechanism of Action
hBD-1 exhibits antimicrobial activity through electrostatic interaction with negatively charged bacterial membranes, leading to membrane disruption and microbial killing. Unlike inducible defensins, hBD-1 is constitutively expressed, providing constant baseline defense. The peptide also binds to chemokine receptor CCR6 on dendritic cells and T cells, linking innate and adaptive immunity.
Biological Role
hBD-1 is expressed in epithelial cells of the skin, respiratory tract, urogenital tract, and gastrointestinal tract. It is the most abundantly expressed defensin in the urinary tract and plays a critical role in mucosal defense. Reduced hBD-1 expression has been associated with increased susceptibility to urinary tract infections and inflammatory bowel disease.
Clinical Relevance
- Urinary tract infections: Reduced hBD-1 levels correlate with recurrent UTIs
- Inflammatory bowel disease: Altered expression in Crohn’s disease and ulcerative colitis
- Oral defense: Constitutively expressed in gingival epithelium
- Cancer: Potential tumor suppressor role in certain epithelial cancers
Pharmacology
hBD-1 has broad-spectrum activity against gram-positive and gram-negative bacteria, though generally weaker than inducible defensins hBD-2 and hBD-3. Activity is enhanced at low salt concentrations and reduced in high-salt environments. The peptide retains activity under reducing conditions that would inactivate alpha-defensins.
References
- Bensch, K.W., et al. (1995). hBD-1: a novel beta-defensin from human plasma. FEBS Letters, 368, 331-335.
- Valore, E.V., et al. (1998). Human beta-defensin-1: an antimicrobial peptide of urogenital tissues. Journal of Clinical Investigation, 101, 1633-1642.
Test Your Knowledge
Reinforce what you learned about Human Beta-Defensin 1 with interactive quizzes on Wikipept.
Take a Quiz on Wikipept